Entering text into the input field will update the search result below


Jul. 18, 2013 7:54 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Deep Value, Special Situations, Biotech

Seeking Alpha Analyst Since 2008

Wall Street Teacher (a pseudonym) worked on Wall Street for several years in the fixed income area and now teaches and writes on financial topics (primarily regulation and markets). Current interests include the psychology of financial markets, the origins of chemistry/physics, synthetic biology, human evolution,siege engines, antique prints, truffles, old cameras, debunking "short and distort" hit pieces, picking RJ Kirk's brain, Battlefield III (we all have our vices) and horology.

Strength in Ziopharm continues to puzzle me. Perhaps a halo effect from Intrexon's S-1 filing? I remain hopeful that Pali ends up creating value. Looking for readout in brain cancer later this Fall.

Disclosure: I am long ZIOP.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.